Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV)-mediated CRISPR-Cas9 editing holds promise to treat many diseases. The immune response to bacterial-derived Cas9 has been speculated as a hurdle for AAV-CRISPR therapy. However, immunological consequences of AAV-mediated Cas9 expression have thus far not been thoroughly investigated in large mammals. We evaluate Cas9-specific immune responses in canine models of Duchenne muscular dystrophy (DMD) following intramuscular and intravenous AAV-CRISPR therapy. Treatment results initially in robust dystrophin restoration in affected dogs but also induces muscle inflammation, and Cas9-specific humoral and cytotoxic T-lymphocyte (CTL) responses that are not prevented by the muscle-specific promoter and transient prednisolone immune suppression. In normal dogs, AAV-mediated Cas9 expression induces similar, though milder, immune responses. In contrast, other therapeutic (micro-dystrophin and SERCA2a) and reporter (alkaline phosphatase, AP) vectors result in persistent expression without inducing muscle inflammation. Our results suggest Cas9 immunity may represent a critical barrier for AAV-CRISPR therapy in large mammals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, it was recently shown that tissue-speci fi c promoter could not reduce immune responses in a canine study using AAV delivery of the CRISPR system (172).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [172]
In the citing paper
“AAV is also being developed as a delivery platform for in vivo gene editing in humans, raising the possibility of T cell responses against the editors, which are typically nucleases of bacterial origin.20,21”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [21]
In the citing paper
“This study indicated that older animals in a study are more likely to be positive for anti-Cas9 antibodies than the younger ones [5].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [5]
In the citing paper
“An animal study conducted on 78 adult canines (60 WT and 18 models for Duchenne muscular dystrophy (DMD)) reported pre-existing anti-SpCas9 antibodies in all animals, but not in 16 newborn puppies, which only had moderate levels of maternally-derived Cas9 antibodies that dropped between two and six weeks of age.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [5]
In the citing paper
“Both humoral and cellular immune responses were still observed, and reduced transduction efficiency was reported [5].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962 · cited 1×
“Numbers (1, 2, 3, 4) in b–g are muscle block numbers.”
BackgroundESEfinder: a web resource to identify exonic splicing enhancers
Cartegni, L. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg616 · Cited by 1,603
Duan, D., Goemans, N., Takeda, S., Mercuri, E., & Aartsma-Rus, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00248-3 · Cited by 1,312
Self-citationComparing an Individual's Test Score Against Norms Derived from Small Samples
Crawford, J. R., & Howell, D. C. (1998) · The Clinical Neuropsychologist · doi:10.1076/clin.12.4.482.7241 · Cited by 1,264
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Self-citationThe promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126 · cited 1×
“Numbers (1, 2, 3, 4) in b–g are muscle block numbers.”
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
Cited by
Past, present, and future of CRISPR genome editing technologies
Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609
“90,91 Several strategies for overcoming pre-existing immunity have been proposed, for example, engineering Cas9 to eliminate immunogenic epitopes, modulating the immune responses, as well as limiting the duration of Cas9 expression.”
BackgroundLethal immunotoxicity in high-dose systemic AAV therapy
Duan, D. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.015 · Cited by 240
Self-citationCRISPR/Cas9 systems: Delivery technologies and biomedical applications
Du, Y., Liu, Y., Hu, J., Peng, X., & Liu, Z. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100854 · Cited by 197
CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
Arjomandnejad, M., Kopec, A. L., & Keeler, A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020287 · Cited by 171
Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges
Mengstie, M. A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.895713 · Cited by 168
Metadata
- Authors
- Hakim, C. H., Kumar, S. R. P., Pérez-López, D. O., Wasala, N. B., Zhang, D., Yue, Y., Teixeira, J., Pan, X., Zhang, K., Million, E. D., Nelson, C. E., Metzger, S., Han, J., Louderman, J. A., Schmidt, F., Feng, F., Grimm, D., Smith, B. F., Yao, G., Yang, N. N., Gersbach, C. A., Chen, S.-J., Herzog, R. W., & Duan, D.
- Affiliations
- National Institutes of Health (US)
- Indiana University Indianapolis (US)
- University of Missouri (US)
- Duke University (US)
- Heidelberg University (DE)
- Auburn University (US)
- Corresponding author
- Duan, Dongsheng
- ORCID
- Venue
- Nature Communications
- Published
- 2021-11-24
- Volume
- 12
- Issue
- 1
- Pages
- 6769-6769
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8613397
- OpenAlex
- W3216412686
- Cited by
- 175
- References
- 57
- Citations by year
- 2026: 28 · 2025: 39 · 2024: 37 · 2023: 36 · 2022: 31 · 2021: 4
- FWCI
- 15.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM008396)
- University of Missouri Life Science Fellowship
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS-90634)
- U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR-70517)
- Parent Project Muscular Dystrophy (no number)
- U.S. Department of Defense (MD150133)
- Hope for Javier, Jackson Freel DMD Research Fund, Team Joseph, Charley’s Fund, Zubin’s Wish, Jett Foundation, Cure Duchenne, and Destroy Duchenne
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Duchenne muscular dystrophy, canine model, dystrophin restoration, muscle inflammation, cytotoxic T lymphocytes, humoral immune response, muscle-specific promoter, microdystrophin, SERCA2a, alkaline phosphatase reporter
- MeSH terms
- Gene Editing, Dependovirus, Animals, Disease Models, Animal, Dogs, Genetic Vectors, Humans, Genetic Therapy, Dystrophin, Genes, Reporter, Muscle, Skeletal, Muscular Dystrophy, Duchenne, Sarcoplasmic Reticulum Calcium-Transporting ATPases, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. https://app.cochat.ai/papers/10.1038/s41467-021-26830-7
- The paper
- Hakim, C. H., Kumar, S. R. P., Pérez-López, D. O., Wasala, N. B., Zhang, D., Yue, Y., Teixeira, J., Pan, X., Zhang, K., Million, E. D., Nelson, C. E., Metzger, S., Han, J., Louderman, J. A., Schmidt, F., Feng, F., Grimm, D., Smith, B. F., Yao, G., . . . Duan, D. (2021). Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nature Communications. https://doi.org/10.1038/s41467-021-26830-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.